BIVI
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- BioVie reported topline results from the Phase 2 ADDRESS-LC trial of bezisterim for neurological symptoms associated with Long COVIDSep 15, 2026
- BioVie provided an update on its Phase 3 development program for Parkinson's diseaseSep 8, 2026
- BioVie completed the treatment phase of the ADDRESS-LC trial of bezisterim for neurological symptoms associated with long COVIDAug 31, 2026
- BioVie reported topline Phase 2 SUNRISE-PD results for bezisterim in early Parkinson's diseaseAug 6, 2026
- BioVie completes enrollment in the ADDRESS-LC trial of bezisterim for neurological symptoms linked to long COVIDMay 26, 2026